As of Friday close, Magenta Therapeutics Inc.’s (NASDAQ:MGTA) stock was down -$0.05, moving down -5.67 percent to $0.75. The average number of shares traded per day over the past five days has been 314,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0540 fall in that time frame. In the last twenty days, the average volume was 282,690, while in the previous 50 days, it was 294,386.
Since last month, MGTA stock retreated -8.40%. Shares of the company fell to $0.7291 on 08/18/23, the lowest level in the past month. A 52-week high of $2.22 was reached on 02/03/23 after having rallying from a 52-week low of $0.32. Since the beginning of this year, MGTA’s stock price has risen by 90.13% or $0.3560, and marked a new high 10 times. However, the stock has declined by -66.14% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
MGTA stock investors should be aware that Magenta Therapeutics Inc. (MGTA) stock had its last reported insider trading activity 192 days ago on Feb 08. Third Rock Ventures IV, L.P., the 10% Owner of the company, disposed of 1,500,000 shares for $0.82 on Feb 08. It resulted in a $1,230,000 divestment by the insider. Third Rock Ventures IV, L.P. sold 2,200,000 shares at an average price of $0.83 on Feb 07. The insider now owns 4,558,204 shares following the transaction.
Financial Health
In the three months ended June 29, Magenta Therapeutics Inc.’s quick ratio stood at 19.50, while its current ratio was 19.50, showing that the company is able to pay off its debt.
While analysts expected Magenta Therapeutics Inc. to report -$0.19 quarterly earnings, the actual figure was -$0.05 per share, beating the consensus estimate by 73.70%. The liabilities of Magenta Therapeutics Inc. were 4.03 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $60.66 million.
Technical Picture
This quick technical analysis looks at Magenta Therapeutics Inc.’s (MGTA) price momentum. With a historical volatility rate of 36.62%, the RSI 9-day stood at 32.27% on 18 August.
With respect to its five-day moving average, the current Magenta Therapeutics Inc. price is down by -6.71% percent or -$0.0540. At present, MGTA shares trade -5.55% below its 20-day simple moving average and -4.94% percent below its 100-day simple moving average. However, the stock is currently trading approximately +5.43% above its SMA50 and -41.78% below its SMA200.
Stochastic coefficient K was 24.58% and Stochastic coefficient D was 27.19%, while ATR was 0.0363. Given the Stochastic reading of 18.11% for the 14-day period, the RSI (14) reading has been calculated as 40.14%.
Analyst Ratings
Magenta Therapeutics Inc. downgraded its rating on Magenta Therapeutics Inc. (NASDAQ: MGTA) to a Neutral in a note to investors on August 25, 2022. The analysts firm previously had a Buy rating on the stock.Magenta Therapeutics Inc. (MGTA) has been rated Hold by analysts. According to 0 brokerage firms, MGTA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Magenta Therapeutics Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $1.00. Based on these forecasts, analysts predict Magenta Therapeutics Inc. (MGTA) will achieve an average price target of $1.00.
